Black patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups (P for interaction=0.19).
RCT
Does spironolactone have similar efficacy and safety in black and nonblack patients with HFpEF?
In patients with HFpEF, black patients have a higher baseline risk of HF hospitalization than nonblack patients, but derive similar efficacy and safety benefits from spironolactone.
valor p: p=0.19
BACKGROUND: Black patients have been shown to have different baseline characteristics and outcomes compared with nonblack patients in cohort studies. However, few studies have focused on heart failure (HF) with preserved ejection fraction (HFpEF) patients. We aimed to determine the difference in cardiovascular outcomes in black and nonblack patients with HFpEF and to determine the relative efficacy and safety of spironolactone in black and nonblack patients. METHODS AND RESULTS: for interaction=0.19). The risk of hyperkalemia and worsening renal function with spironolactone and study drug adherence were also similar. CONCLUSIONS: Black patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Lewis et al. (Thu,) conducted a rct in Heart failure with preserved ejection fraction (HFpEF). Spironolactone was evaluated on Cardiovascular outcomes (p=0.19). Black patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups (P for interaction=0.19).